Last reviewed · How we verify
NCT03862989: CPS
Facilitating Catheter Guidance to Optimal Site for VT Ablation
trial testing Radiofrequency catheter ablation in Post-myocardial Infarction Ventricular Tachycardia. Withdrawn.
1 November 2021
Quick facts
| Lead sponsor | University of Exeter |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 May 2021 |
| Primary completion | 1 November 2021 |
| Estimated completion | 1 November 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Radiofrequency catheter ablation
Conditions studied
- Post-myocardial Infarction Ventricular Tachycardia — all drugs for Post-myocardial Infarction Ventricular Tachycardia →
Sponsor
University of Exeter
Who can join
18 and older, any sex, with Post-myocardial Infarction Ventricular Tachycardia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Each year in the UK, approximately 150,000 people have a heart attack when the blood supply to their heart is compromised. As a result, affected regions of the heart can become diseased and scarred. In a healthy person, electrical waves propagate across the heart in a regulated pattern which triggers contraction to pump blood around the body. The scar tissue that forms as a result of a heart attack can disrupt the propagation of the electrical waves. If significant disruptions occur, blood cannot be pumped out of the body effectively, leading to sudden death. Ablation therapy aims to eliminate areas of diseased tissue that cause disruption to the heart rhythm, by applying radiofrequency using catheters inserted into the heart. The most accurate techniques used to locate the region to ablate require the induction of dangerous heart rhythms, which are only inducible in about 65% of people. Pace mapping is a technique used to locate regions to ablate, which can be performed during normal heart rhythm. ECG data, which records electrical signals from the heart, is collected when the patient has an abnormal heart rhythm. From this template ECG, a clinician can tell the approximate location of the diseased tissue. A catheter is directed to that location, the heart stimulated, and another ECG, called the paced ECG is recorded. If the paced ECG matches the template ECG, it is assumed that the heart was paced in the location that requires ablation. Current ablation techniques are difficult, time consuming, and inaccurate. As a result, the procedure may work in only half of all patients, and result in unnecessary damage to healthy tissue, leading to later impairment of heart function. The CPS project's overall goal is to increase the success rates of ablation therapy by improving the accuracy and efficiency of locating the optimal region of tissue to eliminate during the pace mapping procedure. Increasing ablation therapy success rates will mean that patients will be unlikely to suffer from future heart rhythm disorders as a result of their heart attack, increasing the life expectancy of heart attack patients. Excess damage caused to the heart as a result of unnecessary ablation lesions will be limited, decreasing the likelihood of future complications. In addition, dangerous heart rhythms do not need to be induced in the patient, significantly decreasing the risk of death during the treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03862989
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Radiofrequency catheter ablation
Trials testing the same drug.
- NCT06864429 — Impact of Catheter Ablation of Frequent Premature Ventricular Complexes in Treating Subtle Left Cardiomyopathy · NA · completed
- NCT05685134 — Epicardial Radiofrequency Catheter Ablation in Patients With Brugada Syndrome · NA · active not recruiting
- NCT03554330 — Combined Use of Radiofrequency-ablation and Balloon-septostomy in the Creation of a Stable Inter-atrial Communication · NA · unknown
- NCT03389074 — Evaluation of Optimal Ablation Index for Pulmonary Vein Isolation in Patients With AF Prospective Registry · unknown
Other University of Exeter trials
Trials by the same sponsor.
- NCT07457437 — Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment · NA · recruiting
- NCT06478121 — Understanding Beta Cell Disorders Through the Study of Rare Genotypes (ENDURE) · recruiting
- NCT06965699 — The Effect of a Plant-based, Protein-dense Sauce on Essential Amino Acid Concentrations and Gut Fullness in Older Adults · NA · recruiting
- NCT06846294 — Obesity Prevention in Children and Young People Treated for Acute Lymphoblastic Leukaemia with ALLTogether · NA · not yet recruiting
- NCT06852547 — The Effect of Ingesting a Novel Algae Protein Source on Rested and Exercised Muscle Protein Synthesis Rates in Older Adu · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03862989 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Exeter
- Last refreshed: 23 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03862989.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing